OBJECTIVE: To discuss the clinical safety about repairing the @entity1897 with the acellular allogeneic nerve. METHODS: The 41 @entity1 (male 38, female 3, age 10 - 55 years old, average 28.9 years old) who were performed chemically extracted acellular nerve allograft transplanting to repair nerve defects from 2002 to 2011. The average interval from @entity128 was 4.1 months (range, 10 hours to 9 months). There were 41 cases nerve defects including 10 brachial plexus nerves, 3 radial nerves of upper arm, 4 ulnar nerves of forearm, 12 @entity2096 , 3 tibial nerves and 5 common peroneal nerves. There were 12 cases combined @entity174 and 20 soft tissue @entity130 . The average length of the nerve allograft to bridge the nerve defects was 6.1 cm (range, 2 - 10 cm). No immunosuppressive drugs were used in all cases. The clinical safety was evaluated through physical examination, blood biochemistry and immunity detection. RESULTS: All cases were followed up post-operation. They got primary wound healing except 2 superficial infection who got delay healing through dressings changing. No any adverse effects happened including immunological rejection, @entity56 , hepatotoxicity and nephrotoxicity. CONCLUSIONS: It is safe and feasible to repairing @entity1 @entity1897 with chemically extracted acellular nerve allograft.

[Clinical safety about repairing the XXXX with chemically extracted acellular nerve allograft].

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures'] @entity128 :: ('MESH:D020209', 'Disease') :: ['injury to nerve repairing'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral nerve defects'] @entity56 :: ('MESH:D004342', 'Disease') :: ['hypersensitivity reaction, deep infection'] @entity2096 :: ('MESH:D020428', 'Disease') :: ['digital and toe nerves, 2 sciatic nerves, 2 femoral nerves'] @entity130 :: ('MESH:D014947', 'Disease') :: ['injury or defects']
@entity1897 :: (MESH:D010523,Disease) :: ['peripheral nerve defects']
